ユーイング肉腫治療の世界市場:併用療法、単独療法

LINEで送る

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

Combination therapy – Market size and forecast 2018-2023

Monotherapy – Market size and forecast 2018-2023

Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 10: MARKET TRENDS

Strong pipeline

Emergence of regenerative therapies

Advent of CRISPR-Cas9 technology

PART 11: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 12: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Amneal Pharmaceuticals Inc.

Baxter International Inc.

Bristol-Myers Squibb Co.

Eli Lilly and Co.

Merck & Co., Inc.

Mylan NV

Novartis AG

Pfizer Inc.

Sun Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd.

PART 13: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 14: EXPLORE TECHNAVIO

Exhibit 01: Product Overview

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Type – Market share 2018-2023 (%)

Exhibit 19: Comparison by type

Exhibit 20: Combination therapy – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Combination therapy – Year-over-year growth 2019-2023 (%)

Exhibit 22: Monotherapy – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Monotherapy – Year-over-year growth 2019-2023 (%)

Exhibit 24: Market opportunity by type

Exhibit 25: Customer landscape

Exhibit 26: Market share by geography 2018-2023 (%)

Exhibit 27: Geographic comparison

Exhibit 28: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 29: North America – Year-over-year growth 2019-2023 (%)

Exhibit 30: Top 3 countries in North America

Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 33: Top 3 countries in Europe

Exhibit 34: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 35: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 36: Top 3 countries in Asia

Exhibit 37: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 38: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 39: Top 3 countries in ROW

Exhibit 40: Key leading countries

Exhibit 41: Market opportunity

Exhibit 42: Impact of drivers and challenges

Exhibit 43: Vendor landscape

Exhibit 44: Landscape disruption

Exhibit 45: Vendors covered

Exhibit 46: Vendor classification

Exhibit 47: Market positioning of vendors

Exhibit 48: Amneal Pharmaceuticals Inc. – Vendor overview

Exhibit 49: Amneal Pharmaceuticals Inc. – Business segments

Exhibit 50: Amneal Pharmaceuticals Inc. – Organizational developments

Exhibit 51: Amneal Pharmaceuticals Inc. – Segment focus

Exhibit 52: Amneal Pharmaceuticals Inc. – Key offerings

Exhibit 53: Amneal Pharmaceuticals Inc. – Key customers

Exhibit 54: Baxter International Inc. – Vendor overview

Exhibit 55: Baxter International Inc. – Business segments

Exhibit 56: Baxter International Inc. – Organizational developments

Exhibit 57: Baxter International Inc. – Segment focus

Exhibit 58: Baxter International Inc. – Key offerings

Exhibit 59: Baxter International Inc. – Key customers

Exhibit 60: Bristol-Myers Squibb Co. – Vendor overview

Exhibit 61: Bristol-Myers Squibb Co. – Business segments

Exhibit 62: Bristol-Myers Squibb Co. – Organizational developments

Exhibit 63: Bristol-Myers Squibb Co. – Geographic focus

Exhibit 64: Bristol-Myers Squibb Co. – Key offerings

Exhibit 65: Bristol-Myers Squibb Co. – Key customers

Exhibit 66: Eli Lilly and Co. – Vendor overview

Exhibit 67: Eli Lilly and Co. – Business segments

Exhibit 68: Eli Lilly and Co. – Organizational developments

Exhibit 69: Eli Lilly and Co. – Geographic focus

Exhibit 70: Eli Lilly and Co. – Segment focus

Exhibit 71: Eli Lilly and Co. – Key offerings

Exhibit 72: Eli Lilly and Co. – Key customers

Exhibit 73: Merck & Co. Inc. – Vendor overview

Exhibit 74: Merck & Co. Inc. – Business segments

Exhibit 75: Merck & Co. Inc. – Organizational developments

Exhibit 76: Merck & Co. Inc. – Geographic focus

Exhibit 77: Merck & Co. Inc. – Segment focus

Exhibit 78: Merck & Co. Inc. – Key offerings

Exhibit 79: Merck & Co. Inc. – Key customers

Exhibit 80: Mylan NV – Vendor overview

Exhibit 81: Mylan NV – Product segments

Exhibit 82: Mylan NV – Organizational developments

Exhibit 83: Mylan NV – Geographic focus

Exhibit 84: Mylan NV – Segment focus

Exhibit 85: Mylan NV – Key offerings

Exhibit 86: Mylan NV – Key customers

Exhibit 87: Novartis AG – Vendor overview

Exhibit 88: Novartis AG – Business segments

Exhibit 89: Novartis AG – Organizational developments

Exhibit 90: Novartis AG – Geographic focus

Exhibit 91: Novartis AG – Segment focus

Exhibit 92: Novartis AG – Key offerings

Exhibit 93: Novartis AG – Key customers

Exhibit 94: Pfizer Inc. – Vendor overview

Exhibit 95: Pfizer Inc. – Business segments

Exhibit 96: Pfizer Inc. – Organizational developments

Exhibit 97: Pfizer Inc. – Geographic focus

Exhibit 98: Pfizer Inc. – Segment focus

Exhibit 99: Pfizer Inc. – Key offerings

Exhibit 100: Pfizer Inc. – Key customers

Exhibit 101: Sun Pharmaceutical Industries Ltd. – Vendor overview

Exhibit 102: Sun Pharmaceutical Industries Ltd. – Business segments

Exhibit 103: Sun Pharmaceutical Industries Ltd. – Organizational developments

Exhibit 104: Sun Pharmaceutical Industries Ltd. – Geographic focus

Exhibit 105: Sun Pharmaceutical Industries Ltd. – Key offerings

Exhibit 106: Sun Pharmaceutical Industries Ltd. – Key customers

Exhibit 107: Teva Pharmaceutical Industries Ltd. – Vendor overview

Exhibit 108: Teva Pharmaceutical Industries Ltd. – Business segments

Exhibit 109: Teva Pharmaceutical Industries Ltd. – Organizational developments

Exhibit 110: Teva Pharmaceutical Industries Ltd. – Segment focus

Exhibit 111: Teva Pharmaceutical Industries Ltd. – Key offerings

Exhibit 112: Teva Pharmaceutical Industries Ltd. – Key customers

Exhibit 113: Validation techniques employed for market sizing

Exhibit 114: Definition of market positioning of vendors




※当サイトのレポート紹介カバレッジ
■産業:医療、IT、電子、自動車、産業機械、建設、消費財、食品、化学、材料、エネルギー、金融、サービスなど多様
■地域:世界市場、アジア市場、中国市場、欧州市場、北米市場、中南米市場、中東市場、アフリカ市場など全世界
■レポート種類:市場動向、規模、占有率、トレンド、将来展望、未来予測、業界分析、産業分析、企業分析、事業機会分析、戦略提言など多様